Oxaliplatino Kabi

Oxaliplatin, the active ingredient in Oxaliplatino Kabi, is a platinum-based chemotherapy agent presented as a 100 mg powder for intravenous infusion use. It treats colorectal cancer and other solid tumours in adult patients. GNH USA supplies Oxaliplatino Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

GNH USA supplies Oxaliplatino Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

Oxaliplatin is a platinum‑based chemotherapeutic that interferes with DNA replication in malignant cells.

- Colorectal cancer: used in combination regimens to shrink tumours and prolong survival. - Gastric cancer: part of multi‑drug protocols to improve response rates. - Pancreatic cancer: incorporated into neoadjuvant or adjuvant therapy to reduce recurrence risk.

Oxaliplatin may cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects: - Nausea and vomiting: often mild to moderate and manageable with anti‑emetics. - Peripheral neuropathy: tingling or numbness, typically dose‑related and reversible after treatment cessation. - Diarrhoea: may require supportive care and hydration. - Fatigue: generalised tiredness experienced during therapy cycles. - Thrombocytopenia: reduced platelet count, increasing bleeding risk. - Neutropenia: lowered neutrophil levels, raising infection susceptibility.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: anaphylaxis or bronchospasm requiring immediate medical intervention. - Acute pulmonary toxicity: rare lung inflammation presenting with dyspnoea. - Cardiac arrhythmias: uncommon but potentially serious rhythm disturbances. - Hemolytic‑uremic syndrome: extremely rare microangiopathic complication. - Renal failure: acute kidney injury in predisposed patients. - Secondary malignancies: long‑term risk of therapy‑related leukaemia.

Oxaliplatin requires careful monitoring and patient education before and during therapy.

- Renal function: assess creatinine clearance before each cycle and adjust if impaired. - Hepatic function: evaluate liver enzymes, especially in patients with metastasis. - Neuropathy risk: monitor for sensory changes; dose modify if severe. - Pregnancy and lactation: avoid use; discuss contraception and breastfeeding cessation. - Drug interactions: review concomitant medications for potential additive toxicities. - Storage: Store below 25°C: keep in the original container, protect from moisture and light.

Oxaliplatin can interact with several drug classes, altering efficacy or toxicity.

Major Interactions (Avoid): - Aminoglycoside antibiotics: may increase risk of ototoxicity and nephrotoxicity. - High‑dose vitamin C infusions: can reduce platinum‑drug activity by chelation.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): heightened bleeding risk due to thrombocytopenia. - NSAIDs: may exacerbate renal impairment. - Anticonvulsants (e.g., carbamazepine): potential for altered drug clearance. - Radiotherapy: concurrent use may amplify neuro‑toxicity. - Herbal supplements (e.g., St. John’s wort): possible induction of metabolic pathways affecting drug levels.